Biomarkers associated with checkpoint inhibitors.
Checkpoint inhibitors (CPI), namely anti-CTLA4 and anti-PD1/PD-L1 antibodies, demonstrated efficacy across multiple types of cancer. However, only subgroups of patients respond to these therapies. Additionally, CPI can induce severe immune-related adverse events (irAE). Biomarkers that predict efficacy and toxicity may help define the patients who may benefit the most from these costly and potentially toxic therapies. In this study, we review the main biomarkers that have been associated with the efficacy (pharmacodynamics and clinical benefit) and the toxicity (irAE) of CPIs in patients.
Department of Hematology, CHU Rennes, Rennes.
G
G
Manson
Department of Hematology, CHU Rennes, Rennes.
J
J
Norwood
Department of Drug Development, DITEP, Gustave Roussy Cancer Campus (GRCC), Villejuif INSERM U1015, Gustave Roussy Cancer Institute, Villejuif, France.
A
A
Marabelle
Division of Oncology, Department of Medicine, Stanford University, Stanford, USA.
H
H
Kohrt
Department of Hematology, CHU Rennes, Rennes INSERM, U917, Rennes, France roch.houot@chu-rennes.fr.
R
R
Houot
D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000235:genetics* / Q000276:immunology; D014408:Biomarkers, Tumor / Q000235:genetics / Q000276:immunology; D060908:CTLA-4 Antigen / Q000235:genetics* / Q000276:immunology; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000235:genetics* / Q000276:immunology / Q000628:therapy; D061026:Programmed Cell Death 1 Receptor / Q000235:genetics* / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018797:Cell Cycle Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor
biomarkers; cancer; checkpoint inhibitors; immunotherapy